Navigation Links
Vion Pharmaceuticals Reports 2009 First Quarter Results
Date:5/11/2009

l for its products, particularly Onrigin (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible delays in the FDA's review process beyond our expectation for approval in December 2009, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, and "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:         Vion Pharmaceuticals, Inc.
                             Alan Kessman, Chief Executive Officer
                             Howard B. Johnson, President & CFO
                             (203) 498-4210


                             VION PHARMACEUTICALS, INC.
                     
'/>"/>
SOURCE  Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related medicine news :

1. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
5. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
6. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
8. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
9. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
10. Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Multi-purpose bilingual coloring books design...the business community to educate - inform parents...Safety issues to Dinosuars to ABC,S and a host of ...is, MO (PRWEB) November 27, 2009 -- Today’s ...to keep them busy any hour of the day, but one of ...
(Date:11/26/2009)...ON, N.J., Nov. 27 The diabetes pop...er the next 25 years and annual medical spending o... from $113 billion today, according to a study pub...The National Changing Diabetes ® Program (NC...nalysis by a team from the University of Chicago. ...
(Date:11/26/2009)...ill when on an emotional rollercoaster, study find... -- Call it the fear factor meets the jubilant spo... -- especially those who root for the winning team...ely contested match and victory was in doubt, prod...w on that this Thanksgiving weekend as you,re glue...
(Date:11/26/2009)... Benton Communications announces a highly effe...r retailers struggling to make an economic recover... 2009 -- Flu fears is the type of challenge that c...om, according to Dr. David Benton, business growth...growth system – The Rfactor Intensive . &...
(Date:11/25/2009)...LLE, Calif., Nov. 25 O...nnounced that the company will host two investor e... December 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,...sentations surrounding carfilzomib in relapsed and...e 51st American Society of Hematology (ASH) Annual...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...of Brisbane-based researchers are conducting a stu...r obese and overweight people. // Pfizer Aust...f $55,000 has been given to Dr Clair Sullivan from...ivan's work is to understand the link between obes...
...s very little significant difference found with re...anesthesia employed during C-section. Some women, ...r C-section //with general anesthesia and some ex...ted to regional or general anesthesia used during ...
...ers have discovered the main culprit for nerve fib...d by the body's own immune system, which is vital ...ment of a severe disease. The study indicated the ...nging about natural death of these cells. Study is...
... A novel HIV study has demonstrated how intense st...es the leeway to the virus to survive harm and tak...anced stages of AIDS. // The study, which uses a c...ch, which is slated for publication in Physical Re...
... at high-risk of developing pulmonary complication...ss graft surgery can reduce their risk through bre... before the operation, according to a study. ...mplications (PPCs) has remained stable, possibly b...
...on Dengue', State's war against mosquitoes has bee...jasekhara Reddy on Friday formally from the Jali H...stituency here. // The operation will also inc...c bins. Garbage collectors on cycle rickshaws will...
Other Medicine News:Health News:Choice of Anesthesia in C-section 2Health News:Choice of Anesthesia in C-section 3Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 2Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 3Health News:HIV Takes Advantage of Rivalry among T cells 2Health News:HIV Takes Advantage of Rivalry among T cells 3Health News:Breathing Training Helps Decrease Risk of Complications After Graft Surgery 2Health News:YSR launches 'Operation Dengue' 2
(Date:11/25/2009)...N, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- C..." or "the Company") (Nasdaq: CSKI ), a,leading fu...nd producing,over-the-counter drugs in the People,...the Company recently passed the Chinese National I...logical Products ("ICPBP") examination,for two of ...
(Date:11/25/2009)...ICK, N.J., Nov. 25 Swissray Intern...ital Radiography ( ddR ) systems, announced today ...e Swiss Investor with a long term view towards gro...tion included all assets and intellectual property...rs of success and growth Swissray is now poised to...
(Date:11/25/2009)..., Nov. 25 Reportlinker.com announc...in its catalogue: ,, Pain Management - Global...220/Pain-Management---Global-Trends.html ,, Wi...of pain management clinics, and the advent of new ...ain management market. Healthcare reforms and reim...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Swissray International Announces New Ownership 2Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6B Braun Medical Wins Two GHX 2009 Best in Class Awards 47992 1B Braun Medical Wins Two GHX 2009 Best in Class Awards 47992 2B Braun Medical Wins Two GHX 2009 Best in Class Awards 47992 3Researchers Detect Blood Clotting Mechanism 47989 1Researchers Detect Blood Clotting Mechanism 47989 2Patrick Johnston Named President and CEO of the California Association of Health Plans 47986 1Patrick Johnston Named President and CEO of the California Association of Health Plans 47986 2
...liver Treatments to Human,Organs -, PHILADELPHIA,...tiny iron-bearing particles to drive healthy cells... done in animals, may lead to,a new method of deli...ed,organs in people., (Photo: http://www.newscom...team, led by Robert J. Levy, M.D., the William J. ...
...hich, last,December 2007, raised $44M in a Series ...ombinant human rod-derived cone viability factor,(...cinal Product from the,European Commission, follow...for the Evaluation of Medicinal Products (EMEA) Co...e treatment of retinitis pigmentosa, a,genetic dis...
Other Medicine Technology:Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 2Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 3
FSH Urine Test - Rapid Test
...s the worlds first miniaturized cardiovascular ult...eatured imaging in a lightweight design. , , ...in cardiovascular care access to complete, real-t... the reach of echocardiography by offering all the...
Myoglobin - Rapid Test
Troponin I - Rapid Test
Medicine Products: